Definium Therapeutics (NASDAQ:DFTX) reported positive topline results from the Phase 3 Panorama study evaluating DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.
Phio Pharmaceuticals (NASDAQ:PHIO) submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration to support the next phase of development for its INTASYL siRNA candidate PH-762.
Telix (NASDAQ:TLX) received U.S. Food and Drug Administration approval for Pixclara, or floretyrosine F 18, as a PET imaging drug for evaluating glioma.
Radiopharm Theranostics (NASDAQ:RADX) reported that RAD101 PET achieved 93% concordance with MRI across all evaluable lesions in an interim Phase 2b analysis, meeting the imaging trial’s primary endpoint.
Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate targeted alpha therapy PSV359 in combination with Keytruda in FAP-α-positive solid tumors.
Digital Realty (NYSE:DLR) formed a strategic joint venture with Rönesans Infrastructure to develop and operate next-generation, carrier-neutral data centers across Türkiye.
BioNTech (NASDAQ:BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in previously treated squamous NSCLC.
Cullinan Therapeutics (NASDAQ:CGEM), Taiho Oncology, and Taiho Pharmaceutical reported that zipalertinib plus chemotherapy improved median progression-free survival by six months versus chemotherapy alone in the Phase 3 REZILIENT3 trial.
Whitehawk Therapeutics (NASDAQ:WHWK) reported WCLC 2026 real-world analyses supporting protein tyrosine kinase 7, or PTK7, as a potential antibody-drug conjugate target in pretreated EGFR wild-type non-small cell lung cancer.
Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PAPILLON results showing median overall survival of 34.3 months with first-line IV RYBREVANT plus carboplatin-pemetrexed versus 27.9 months with chemotherapy alone.
AstraZeneca (NASDAQ:AZN) reported updated Phase III ADAURA results showing TAGRISSO reduced the risk of death by 48% versus placebo after eight years in the overall Stage IB-IIIA EGFR-mutated NSCLC population.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo reported that ENHERTU achieved median progression-free survival of 14.3 months in the Phase III DESTINY-Lung04 lung cancer trial.
